Phase I/II Combination With Irinotecan- Erbitux
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | May 2008 |
| End Date: | December 2012 |
A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs Placebo in Combination With Erbitux and Irinotecan K-Ras Wildtype Subjects With Metastatic Colorectal Cancer
Part 1: To define the recommended dose of brivanib that can be safely administered in
combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic
colorectal cancer (MCRC)
Part 2: To compare median duration of progression free survival (PFS)
combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic
colorectal cancer (MCRC)
Part 2: To compare median duration of progression free survival (PFS)
Inclusion Criteria:
- Biopsy proven MCRC
- Prior irinotecan allowed
- Prior Erbitux allowed
Exclusion Criteria:
- No prior brivanib
- No prior combination of irinotecan with Erbitux
- No secondary malignancies
- No anti-coagulation therapy
- No prior history of blood clots requiring anti-coagulation
We found this trial at
5
sites
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
James Graham Brown Cancer Center No one should feel compelled to leave Kentucky to seek...
Click here to add this to my saved trials
Click here to add this to my saved trials